#

 *August 2018 Enquiries: Chris Pockett, Head of Communications +44 (0)1453 524133*

**Renishaw demonstrates functional stereotactic neurosurgery expertise at ESSFN**

**At the 23rd congress of the** European Society for Stereotactic and Functional Neurosurgery (ESSFN), global engineering company Renishaw will present its range of products for stereotactic neurosurgery. Held in Edinburgh, Scotland from September 26th to 29th, 2018, the event brings together neuroscientists, neurosurgeons and psychiatrists to discuss the latest advances in the field.

**2018 is the first year that the ESSFN congress is jointly organised by neurosurgeons and a psychiatrist. In addition to neurosurgical approaches for psychiatric disorders, the conference will also focus on pain, epilepsy and Parkinson’s disease, with discussion of the latest technological, clinical and scientific advances.**

**At the event, Renishaw will demonstrate the** neuromate® stereotactic robot system that can be used for a range of functional neurosurgery procedures. The system can be used in deep brain stimulation (DBS) for Parkinson’s disease and stereoelectroencephalography (SEEG) for the treatment of epilepsy and delivery of an investigational intraparenchymal drug delivery system.

Also exhibiting on the stand will be DIXI Medical, a manufacturer of specialist electrodes and instruments for use in stereotactic neurosurgery. In the UK and Ireland, Renishaw is the exclusive distributor of DIXI Medical products, including depth electrodes, biopsy needles, cortical grids and accessories.

**“Robotic systems provide a consistent, rapid and precise platform for all surgical neurosurgery applications,” explained Adrian Gut, Global Sales and Marketing Director, Neurosurgery, at Renishaw. “The** neuromate stereotactic robot has been used in thousands of procedures to reduce procedure time and improve accuracy.

**“To support its robot offering, Renishaw also provides** *neuroinspire*™ software for surgical planning,” added Gut. “The software allows surgeons to plan the safest surgical route and enables surgeons to visualise an image of implantable instruments in position. Renishaw’s distribution of DIXI Medical products strengthens its portfolio further, enabling the company to be a rounded supplier of stereotactic neurosurgical products, from planning to delivery.”

**Renishaw offers a range of neurological products including medical devices, software and surgical robotic systems.** For more information on Renishaw’s products for stereotactic neurosurgery, visit [www.renishaw.com/neuro](http://www.renishaw.com/neuro).

Ends 331 words

Notes to editors

UK-based Renishaw is a world leading engineering technologies company, supplying products used for applications as diverse as jet engine and wind turbine manufacture, through to dentistry and brain surgery. It has over 4,500 employees located in the 35 countries where it has wholly owned subsidiary operations.

For the year ended June 2018 Renishaw recorded sales of £611.5 million of which 95% was due to exports. The company’s largest markets are China, the USA, Japan and Germany.

Throughout its history Renishaw has made a significant commitment to research and development, with historically between 14 and 18% of annual sales invested in R&D and engineering. The majority of this R&D and manufacturing of the company’s products is carried out in the UK.

The Company’s success has been recognised with numerous international awards, including eighteen Queen’s Awards recognising achievements in technology, export and innovation.

Further information at [www.renishaw.com](http://www.renishaw.com)